Article
Ras-induced resistance to lapatinib is overcome by MEK inhibition.
Current cancer drug targets - 1 Mar 2010
Zoppoli Gabriele, Moran Eva, Soncini Debora, Cea Michele, Garuti Anna, Rocco Ilaria, Cirmena Gabriella, Grillo Valentina, Bagnasco Luca, Icardi Giancarlo, Ansaldi Filippo, Parodi Silvio, Patrone Franco, Ballestrero Alberto, Nencioni Alessio
Abstract excerpt
Lapatinib, a dual HER2 and EGFR tyrosine kinase inhibitor is highly active in HER2+ breast cancer. However, its efficacy is limited by either primary or acquired resistance. Although mutations in ras genes are rarely found in breast cancer, H-ras overexpression is frequently observed. Moreover, g...
Topics
- Antineoplastic Agents
- Breast Neoplasms
- Butadienes
- Cell Line, Tumor
- Cell Survival
- Cell Transformation, Neoplastic
- Drug Resistance, Neoplasm
- Enzyme Inhibitors
- Female
- Genes, ras
- Humans
- Immunoblotting
- Lapatinib
- Mitogen-Activated Protein Kinase Kinases